Evidence map›Paper›PMID 35848723›Full record

SynthesisNeuropsychopharmacology reports2022

Antidepressants for social anxiety disorder: A systematic review and meta-analysis.

Nobuyuki Mitsui, Yutaka Fujii, Satoshi Asakura, Hissei Imai, Hisashi Yamada, Naoki Yoshinaga, Yoshihiro Kanai, Takeshi Inoue, Eiji Shimizu

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Neuropsychopharmacology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Nobuyuki MitsuiDepartment of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan.ORCID 0000-0002-0788-7690
Yutaka FujiiDepartment of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan.ORCID 0000-0002-3928-7630
Satoshi AsakuraDepartment of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Hissei ImaiDepartment of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine and School of Public Health, Kyoto, Japan.ORCID 0000-0003-3656-5188
Hisashi YamadaDepartment of Neuropsychiatry, Hyogo College of Medicine, Hyogo, Japan.
Naoki YoshinagaSchool of Nursing, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.ORCID 0000-0002-4438-9746
Yoshihiro KanaiDepartment of Human Science, Faculty of Liberal Arts, Tohoku Gakuin University, Sendai, Japan.
Takeshi InoueDepartment of Psychiatry, Tokyo Medical University, Tokyo, Japan.ORCID 0000-0001-5248-1289
Eiji ShimizuCognitive Behavioral Therapy Center, Chiba University Hospital, Chiba, Japan.
Sapporo University · JPChiba University Hospital · JPHyogo Medical University · JPKyoto University · JPTohoku Gakuin University · JPTokyo Medical University · JPUniversity of Miyazaki · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis systematic review is aimed to update and reintegrate the pharmacotherapy of social anxiety disorder (SAD), including the Japanese medical database.

methodsWe conducted a systematic review and meta-analysis of pharmacotherapy of SAD according to the Medical Information Distribution Service. We used data from a most recent systematic review, and updated search were conducted using MEDLINE, PubMed, CENTRAL, ICTRP, and ICHUSHI from August 1st, 2017 to January 31st, 2022. The outcome were response rates assessed by Clinical Global Impressions Improvement, efficacy assessed by the Liebowitz Social Anxiety Scale (LSAS), and dropout rates. We performed a random effect of meta-analysis to obtain the differences in each outcome between active medication and placebo. We used RevMan version 5.3 for analyses.

resultsWe identified 5 studies through update search and performed meta-analysis for 33 studies on selective serotonin reuptake inhibitor (SSRI) and 6 studies on serotonin noradrenalin reuptake inhibitor (SNRI). The response rate (RR = 1.62) and the LSAS score reduction (mean difference = -9.65) of SSRI, and the response rate (RR = 1.57) and the LSAS score reduction (mean difference = -11.72) of SNRI were significantly different from placebo. The dropout rates of SSRI or SNRI were not significant. The response rates of SSRIs in both Japanese studies (RR = 1.44) and countries other than Japan (RR = 1.67) were significant. Most findings were based on low quality of evidence.

conclusionSSRIs are valid option for pharmacotherapy of SAD including Japanese patients. SNRIs are another effective option. However, the results should be interpreted cautiously due to several risk of bias.

Indexed as

Phobia, SocialSerotonin and Noradrenaline Reuptake InhibitorsAntidepressive AgentsHumansJapanSelective Serotonin Reuptake InhibitorsAntidepressive AgentsSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsantidepressantsJapanmeta-analysissocial anxiety disordersystematic review

Identifiers

PMID35848723
PMCPMC9773641
OpenAlexW4285728746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.